Skip to content

Alaunos Therapeutics, Inc.: 10-K filed 2012-02-29

What Alaunos Therapeutics, Inc. reported in its annual report filed 2012-02-29 (fiscal FY 2011): 26 published measures, 92 facts as tagged in accession 0001144204-12-012003.

This filing

Form
10-K (annual report)
Filed
2012-02-29
Fiscal period
fiscal FY 2011
Accession
0001144204-12-012003 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Alaunos Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-31108,108,000USD
At 2010-12-3161,520,000USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2011-12-3136,501,000USD
At 2010-12-3130,967,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-3171,607,000USD
At 2010-12-3130,553,000USD
At 2009-12-3128,104,000USD
At 2008-12-316,739,000USD
At 2007-12-3130,370,000USD
At 2006-12-3126,533,000USD
At 2005-12-317,202,000USD
At 2004-12-31-144,000USD
At 2003-12-31340,000USD
At 2003-09-09500,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-31104,713,000USD
At 2010-12-3160,392,000USD
At 2009-12-3148,839,000USD
At 2008-12-3111,379,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-63,778,000USD365
2003-09-10 to 2011-12-31-187,592,000USD3035
2010-01-01 to 2010-12-31-32,670,000USD365
2009-01-01 to 2009-12-31-7,649,000USD365
2008-01-01 to 2008-12-31-25,231,000USD366
2007-01-01 to 2007-12-31-26,608,000USD365
2006-01-01 to 2006-12-31-17,857,000USD365
2005-01-01 to 2005-12-31-9,517,000USD365
2004-01-01 to 2004-12-31-5,687,000USD366
2003-09-10 to 2003-12-31-160,000USD113

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-38,835,000USD365
2003-09-10 to 2011-12-31-142,808,000USD3035
2010-01-01 to 2010-12-31-19,694,000USD365
2009-01-01 to 2009-12-31-12,294,000USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2011-01-01 to 2011-12-311,156,000USD365
2003-09-10 to 2011-12-313,067,000USD3035
2010-01-01 to 2010-12-31186,000USD365
2009-01-01 to 2009-12-3111,000USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-01-01 to 2011-12-31667,000USD365
2003-09-10 to 2011-12-31667,000USD3035

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-01-01 to 2011-12-3184,312,000USD365
2003-09-10 to 2011-12-31250,587,000USD3035
2010-01-01 to 2010-12-3131,433,000USD365
2009-01-01 to 2009-12-3149,765,000USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-1,156,000USD365
2003-09-10 to 2011-12-31-3,066,000USD3035
2010-01-01 to 2010-12-31-186,000USD365
2009-01-01 to 2009-12-31-11,000USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2011-12-311,141,000USD
At 2010-12-31253,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-01-01 to 2011-12-312,759,000USD365
2003-09-10 to 2011-12-3115,301,000USD3035
2010-01-01 to 2010-12-313,637,000USD365
2009-01-01 to 2009-12-312,181,000USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31-71,400,000USD365
2003-09-10 to 2011-12-31-197,027,000USD3035
2010-01-01 to 2010-12-31-24,546,000USD365
2009-01-01 to 2009-12-31-12,123,000USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2011-12-31106,105,000USD
At 2010-12-3160,816,000USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2011-12-3113,363,000USD
At 2010-12-313,612,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2011-12-311,727,000USD
At 2010-12-311,031,000USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2011-01-01 to 2011-12-31274,000USD365
2003-09-10 to 2011-12-312,321,000USD3035
2010-01-01 to 2010-12-311,668,000USD365
2009-01-01 to 2009-12-31380,000USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2011-01-01 to 2011-12-3157,083,000USD365
2003-09-10 to 2011-12-31128,899,000USD3035
2010-01-01 to 2010-12-3112,910,000USD365
2009-01-01 to 2009-12-314,556,000USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2011-12-3169,206,044shares
At 2010-12-3148,466,562shares

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-12-31771,000USD
At 2010-12-31364,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2011-12-3119,425,000USD
At 2010-12-3127,311,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-12-3110,821,000USD
At 2010-12-312,538,000USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2011-12-311,313,000USD
At 2010-12-31424,000USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-01-01 to 2011-12-3114,984,000USD365
2003-09-10 to 2011-12-3168,795,000USD3035
2010-01-01 to 2010-12-3111,636,000USD365
2009-01-01 to 2009-12-317,567,000USD365

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2011-01-01 to 2011-12-3139,000USD365
2003-09-10 to 2011-12-314,714,000USD3035
2010-01-01 to 2010-12-31765,000USD365
2009-01-01 to 2009-12-3113,000USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-01-01 to 2011-12-31696,000USD365
2003-09-10 to 2011-12-311,727,000USD3035
2010-01-01 to 2010-12-31-758,000USD365
2009-01-01 to 2009-12-31-850,000USD365

Inspect the source

Entity
Alaunos Therapeutics, Inc. / CIK 0001107421
Captured
2026-09-20T05:23:32.946Z
SEC response SHA-256
ceac768c7325f34d0f6470e00f80e7e6787b28f3ae115ba65aa7cdfdab90d956

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001107421.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))